1. Белоусов Ю.Б., Моисеев В.С., Лепахин В.К. Клиническая фармакология и фармакотерапия: Руководство для врачей. - М.: Универсум Паблишинг, 2000. С.97-110; 150-152.
2. Кукес В.Г. Клиническая фармакология. – М.: Геотар-Мед, 2004.
3. Коржавых Э.А., Румянцев А.С. Таблетки и их разновидности. Российские аптеки. 2003, ?13, с. 12-16.
4. Сидоренко Б.А., Преображенский Д.В. Антагонисты кальция. - М.: АОЗТ Информатик, 1999. - 176 с.
5. Botero R, Aroca G, Asa G, Gonzalez M. Efficacy and safety of two different formulations of nifedipine (GITS) vs. slow release microgranules in patients with mild and moderate hypertension. J Hum Hypertens 2002;16(suppl 1):S156-60.
6. Breekveldt-Postma NS, Herings RMC. Persistence with antihypertensives related to formulation: the case of nifedipine. Ann Pharmacother. 2005 Feb;39(2):237-42.
7. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to doubleblind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366– 372.
8. Champlain J, Karas M, Nguyen P, et al. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens. 1998;16:1357–1369.
9. ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation. 2003 Jan 28;107(3):422-8.
10. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92: 1326-31.
11. Grundy JS, Foster RT. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceuti cal, pharmacokinetic and pharmacological properties. Clin Pharmacokinet1996;30:28-51.
12. Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, Ilersich AL. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther. 2002 Feb;24(2):302-16.
13. Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA; ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens. 2005 Mar;23(3):641-8.
14. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birdenhager WH, et al. for the Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757–764.
15. Opie L. Drugs for the heart. Philadelphia. -1995.
16. Taniwa T, Miyataka M, Kimura A, Taniguchi M, Hirano Y, Hayashi T, Ishikawa K. Calcium antagonists for secondary prevention of myocardial infarction: is there a need to shift from short-acting to long-acting types? Circ J. 2005 Nov;69(11):1308-14
17. Toal CB, Laplante L. Is there a difference in hypertensive patient compliance between a once a day or twice a day nifedipine? Am J Hypertension 1995;8(4(2)):D17.
